Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the Phase 3 V ...
KFDA approves Takedas Prucalopride capsules for metastatic colorectal cancer Approval granted for Takedas Prucalopride ...
Plus: Maura Healey meets with eds-and-meds leaders about threats to research funding; Takeda sends zebras flying at Celtics ...
US clinical-stage pharma company Protagonist Therapeutics and Japan’s Takeda have announced positive top-line results for the ...
January 24, 2025 Takeda-backed Ascentage Pharma aims to raise ... gets US approval Ascendis Pharma said on Monday the U.S. Food & Drug Administration had approved its therapy to treat adult ...
GOLF.com on MSN18h
Tiger’s voicemail, Keegan’s quandary, TGL impressions | Monday FinishTiger Woods' voicemail made an impression, LIV has a new playoff, I went to TGL, Morikawa's hurting, Keegan Bradley made me ...
Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted ...
Bureaucracy, aversion to risk, high taxes are blamed for why Japan lags behind in the start-up scene. Read more at ...
Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback